Apellis Pharmaceuticals, Inc.
APLSDrugs in Pipeline
7
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
APL-2, Pegcetacoplan
Geographic Atrophy Secondary to Age-related Macular Degeneration
Pegcetacoplan
C3G
PEGCETACOPLAN (APL-2)
Geographic Atrophy Secondary to Age-related Macular Degeneration
APL-2
Paroxysmal Nocturnal Hemoglobinuria
Soliris
Paroxysmal Nocturnal Hemoglobinuria
APL-3007, pegcetacoplan (APL-2)
Geographic Atrophy Secondary to Age-related Macular Degeneration
APL-9
COVID
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
APL-2, Pegcetacoplan | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
Pegcetacoplan | Phase 3 | C3G | - | - |
PEGCETACOPLAN (APL-2) | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
APL-2 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Soliris | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
APL-3007, pegcetacoplan (APL-2) | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | - | - |
APL-9 | Phase 2 | COVID | - | - |
Paroxysmal Nocturnal Hemoglobinuria
2 drugs in this indication
Geographic Atrophy Secondary to Age-related Macular Degeneration
2 drugs in this indication
COVID
1 drug in this indication
C3G
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)